Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $12.25.

SANA has been the topic of several recent analyst reports. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright boosted their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday. They set a "buy" rating and a $7.00 target price for the company.

Insider Buying and Selling

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the business's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares of the company's stock, valued at $29,474,406.39. The trade was a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 31.10% of the stock is currently owned by insiders.

Remove Ads

Institutional Trading of Sana Biotechnology

Institutional investors have recently bought and sold shares of the business. Cornercap Investment Counsel Inc. bought a new stake in shares of Sana Biotechnology during the 3rd quarter worth approximately $67,000. Intech Investment Management LLC bought a new stake in shares of Sana Biotechnology during the 3rd quarter worth approximately $240,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Sana Biotechnology by 11.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company's stock worth $4,359,000 after acquiring an additional 105,382 shares during the period. FMR LLC lifted its holdings in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company's stock worth $131,494,000 after acquiring an additional 4,438,949 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Sana Biotechnology by 17.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company's stock worth $146,000 after acquiring an additional 5,338 shares during the period. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Trading Up 10.6 %

Shares of Sana Biotechnology stock traded up $0.28 during trading on Friday, hitting $2.93. 2,989,692 shares of the stock were exchanged, compared to its average volume of 2,977,744. The stock has a market capitalization of $654.18 million, a price-to-earnings ratio of -2.09 and a beta of 1.63. The company has a fifty day moving average price of $3.03 and a 200-day moving average price of $3.27. Sana Biotechnology has a 1-year low of $1.52 and a 1-year high of $10.50.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.